BUZZ-Sichuan Kelun-Biotech jumps on progress of core product's development

Reuters03-13

** Shares of Chinese drug producer Sichuan Kelun-Biotech Biopharmaceutical Co Ltd jump as much as 15.4% to HK$135.80, highest and biggest one-day gain since March 4

** Stock is the biggest gainer in Hang Seng Composite Index

** Co says its core product SKB264 was recently granted Breakthrough Therapy Designation by the Center for Drug Evaluation of the National Medical Products Administration (NMPA) of China for first-line treatment of breast cancer

** Co also warns of the risk that SKB264 may not ultimately be successfully developed and commercialized

** Hong Kong's healthcare index slips 0.8%, while Hang Seng Composite Index rises 0.6% and Hang Seng Index

adds 0.7%

** Stock up 30.7% YTD

(Reporting by Donny Kwok)

((donny.kwok@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment